PepGen announces presentations of data on EDO platform

PepGen announced key highlights from the upcoming presentation of preclinical non-human primate, or NHP, data supporting PepGen’s proprietary Enhanced Delivery Oligonucleotide, or EDO, platform at the 6th Ottawa International Conference on Neuromuscular Disease and Biology being held on September 7-9, Ottawa, ON, Canada, and at the 2023 Myotonic Dystrophy Foundation Annual Conference being held on September 7-9 in Washington, D.C. In a poster presentation titled “PGN-EDODM1 Nonclinical Data Demonstrate Mechanistic and Meaningful Activity for Potential Treatment of Myotonic Dystrophy Type 1” at MDF and “FREEDOM-DM1: Nonclinical Data Support the Phase 1 Study Design to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PGN-EDODM1 in Adults with Myotonic Dystrophy Type 1 ” at NMD, PepGen reported that the EDO technology enables up to 25-fold higher level of nuclear delivery of oligonucleotides in vitro to myotubes compared to “naked” unconjugated oligonucleotides. Additionally, the presentation reported that EDO technology was also shown to improve in vivo nuclear delivery, with 72% of skeletal muscle nuclei in NHPs positive for oligonucleotide following two doses at 30mg/kg.